Daniela Romero
Physician Assistant · Miami, FLNPI 1699499921
Payments from drug & device makers
Across 129 payments — averaging $41.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Jazz Pharmaceuticals Inc.$1K
- AstraZeneca$468
- Neurelis, Inc.$441
- AbbVie$418
- Boston Scientific$343
- plus $1K from 12 others
What the payments were for
- Food & beverage$5,417100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 31 | $1,662 |
| Jazz Pharmaceuticals Inc. | 24 | $1,002 |
| AstraZeneca | 13 | $468 |
| Neurelis, Inc. | 14 | $441 |
| AbbVie | 17 | $418 |
| Boston Scientific | 2 | $343 |
| Pfizer | 8 | $178 |
| Livanova USA, Inc. | 4 | $171 |
| Atricure, Inc. | 2 | $155 |
| Galderma Laboratories, L.p. | 1 | $150 |
| SK Life Science, Inc. | 5 | $138 |
| Alnylam Pharmaceuticals Inc. | 1 | $125 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Catalyst Pharmaceuticals, Inc. | 1 | $32 |
| Lilly USA, LLC | 1 | $26 |
| Lundbeck LLC | 1 | $20 |
| Amgen | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$373
- WATCHMAN FLX$343
- ANDEXXA$249
- Briviact$247
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$139
- Nayzilam$125
- Fintepla$125
- AMVUTTRA$125
- VALTOCO$121
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$109
How this compares
$5,417 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobazam | 19 | $1,795 |
| DilantinPhenytoin Sodium Extended | 15 | $1,075 |
| Lacosamide | 11 | $958 |
| Levetiracetam | 42 | $889 |
| Nortriptyline Hcl | 13 | $266 |
| Lamotrigine | 15 | $251 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $235 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $168 |
| Gabapentin | 12 | $164 |
| Venlafaxine Hcl | 13 | $109 |
| Topiramate | 14 | $96 |
| Atorvastatin Calcium | 15 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerDilantin | $178 | $1,07515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Miami
- Jeanelle KingMiami$424K
- Dallas GreenMiami$202K
- Paula BrezavscekMiami$127K
- Rita QuintanaMiami$110K
- Carol AntequeraMiami$98K
- Ziyad PeerMiami$89K
- Lisa DavisMiami$81K
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.